stockrowPuma Biotechnology, Inc. (PBYI) vs REGENXBIO Inc. (RGNX)
- Puma Biotechnology, Inc. PBYI 8.27 −15.35%
- REGENXBIO Inc. RGNX 7.56 +2.44%
Puma Biotechnology, Inc. and REGENXBIO Inc. are both Biotechnology companies. Puma Biotechnology, Inc. and REGENXBIO Inc. are of similar size ($504.3M and $487.2M). REGENXBIO Inc. has negative trailing earnings, so its P/E is not meaningful; Puma Biotechnology, Inc. trades at 15.3×. Puma Biotechnology, Inc. grew revenue faster over the last twelve months: −2.86% against −4.59%. Puma Biotechnology, Inc. has the higher net margin (11.6% vs −113.9%) and the higher return on invested capital (42.6% vs 0.00%). Across the 17 metrics below, Puma Biotechnology, Inc. leads on 13 and REGENXBIO Inc. on 4.
Valuation
Profitability
| Metric | PBYI | RGNX | Biotechnology median |
|---|---|---|---|
| Gross margin | 74.83% | 87.54% | 68.51% |
| Operating margin | 13.16% | (95.68%) | 0.00% |
| Net margin | 11.55% | (113.85%) | 0.00% |
| Free cash flow margin | 17.79% | (100.58%) | 0.00% |
| Return on equity | 21.97% | (113.24%) | (51.96%) |
| Return on assets | 13.78% | (35.36%) | (46.06%) |
| Return on invested capital | 42.61% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack